Home

Salarius Pharmaceuticals, Inc. - Common Stock (SLRX)

0.7828
-0.2168 (-21.69%)
NASDAQ · Last Trade: Jul 30th, 7:00 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Specificity Inc. (OTCID: SPTY) AI-Powered Technology Poised to Disrupt the Media Sector – More Stocks Inside
Specificity Inc. (OTCID: SPTY), a next-generation digital marketing firm, has regained its status as a fully reporting SEC current filer—marking a key milestone as it continues to revolutionize audience targeting across digital platforms. Known for eliminating bots and irrelevant impressions, Specificity’s proprietary ad tech delivers precision-targeted ads across display, social, and Connected TV (CTV) to the same verified, high-intent audiences —maximizing ROI and minimizing waste.
Via AB Newswire · July 29, 2025
Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge – Material Gains & More Stocks Inside
Power Metallic Mines Inc. (TSXV: PNPN, OTCQB: PNPNF ) has reached a historic milestone by securing the largest exploration license in Saudi Arabia’s Jabal Sayid Belt , marking a major step in the company’s global expansion strategy. The awarded Jabal Baudan project spans over 200 square kilometers , targeting copper, gold, and zinc in one of the Kingdom’s most mineral-rich regions.
Via AB Newswire · June 17, 2025
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
Ademi LLP is investigating Salarius (NASDAQ: SLRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Decoy Therapeutics.
By Ademi LLP · Via Business Wire · January 13, 2025